Haleon (HLN) Stock Forecast, Price Target & Predictions
HLN Stock Forecast
Haleon stock forecast is as follows: an average price target of $9.15 (represents a -6.25% downside from HLN’s last price of $9.76) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
HLN Price Target
The average price target for Haleon (HLN) is $9.15 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $9.15 to $9.15. This represents a potential -6.25% downside from HLN's last price of $9.76.
HLN Analyst Ratings
According to 7 Wall Street analysts, Haleon's rating consensus is 'Buy'. The analyst rating breakdown for HLN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Haleon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 08, 2024 | Rashad Kawan | Morgan Stanley | $9.15 | $8.29 | 10.37% | -6.25% |
The latest Haleon stock forecast, released on Apr 08, 2024 by Rashad Kawan from Morgan Stanley, set a price target of $9.15, which represents a 10.37% increase from the stock price at the time of the forecast ($8.29), and a -6.25% decrease from HLN last price ($9.76).
Haleon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $9.15 |
| Last Closing Price | $9.76 | $9.76 | $9.76 |
| Upside/Downside | -100.00% | -100.00% | -6.25% |
In the current month, the average price target of Haleon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Haleon's last price of $9.76. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | Deutsche Bank | Hold | Hold | Hold |
| Sep 20, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 06, 2024 | Goldman Sachs | - | Neutral | Downgrade |
| Aug 05, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 02, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 01, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 09, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 09, 2024 | Barclays | Overweight | Overweight | Hold |
| May 02, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Apr 17, 2024 | HSBC | - | Buy | Initialise |
Haleon's last stock rating was published by Deutsche Bank on Oct 08, 2024. The company gave HLN a "Hold" rating, the same as its previous rate.
Haleon Financial Forecast
Haleon Revenue Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $2.99B | $3.79B |
| Avg Forecast | $7.19B | $7.06B | $3.29B | $6.80B | $3.08B | $2.79B | $3.70B | $7.03B | $7.06B | $3.29B | $3.19B | $3.08B |
| High Forecast | $7.19B | $7.06B | $3.29B | $6.80B | $3.08B | $2.79B | $3.70B | $7.03B | $7.06B | $3.29B | $3.19B | $3.08B |
| Low Forecast | $7.19B | $7.06B | $3.29B | $6.80B | $3.08B | $2.79B | $3.70B | $7.03B | $7.06B | $3.29B | $3.19B | $3.08B |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.94% | 1.23% |
Haleon's average Quarter revenue forecast for Jun 23 based on 1 analysts is $3.29B, with a low forecast of $3.29B, and a high forecast of $3.29B. HLN's average Quarter revenue forecast represents a 10.22% increase compared to the company's last Quarter revenue of $2.99B (Mar 23).
Haleon EBITDA Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $637.00M | $619.00M |
| Avg Forecast | $1.41B | $1.39B | $647.62M | $1.34B | $606.28M | $548.08M | $727.51M | $1.38B | $1.39B | $647.62M | $628.01M | $606.28M |
| High Forecast | $1.41B | $1.39B | $647.62M | $1.34B | $606.28M | $548.08M | $727.51M | $1.38B | $1.39B | $647.62M | $628.01M | $606.28M |
| Low Forecast | $1.41B | $1.39B | $647.62M | $1.34B | $606.28M | $548.08M | $727.51M | $1.38B | $1.39B | $647.62M | $628.01M | $606.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.02% |
1 analysts predict HLN's average Quarter EBITDA for Jun 23 to be $647.62M, with a high of $647.62M and a low of $647.62M. This is 1.67% upper than Haleon's previous annual EBITDA (Mar 23) of $637.00M.
Haleon Net Income Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $389.00M | $198.00M |
| Avg Forecast | $1.66B | $1.59B | $884.58M | $1.69B | $1.53B | $674.18M | $823.56M | $1.69B | $1.66B | $885.95M | $742.01M | $14.24B |
| High Forecast | $1.66B | $1.59B | $884.58M | $1.69B | $1.53B | $679.15M | $823.56M | $1.69B | $1.66B | $885.95M | $742.01M | $14.24B |
| Low Forecast | $1.66B | $1.59B | $884.58M | $1.69B | $1.53B | $669.22M | $823.56M | $1.69B | $1.66B | $885.95M | $742.01M | $14.24B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.52% | 0.01% |
Haleon's average Quarter net income forecast for Jun 23 is $885.95M, with a range of $885.95M to $885.95M. HLN's average Quarter net income forecast represents a 127.75% increase compared to the company's last Quarter net income of $389.00M (Mar 23).
Haleon SG&A Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $1.14B | $1.51B |
| Avg Forecast | $2.96B | $2.91B | $1.36B | $2.80B | $1.27B | $1.15B | $1.52B | $2.90B | $2.91B | $1.36B | $1.31B | $1.27B |
| High Forecast | $2.96B | $2.91B | $1.36B | $2.80B | $1.27B | $1.15B | $1.52B | $2.90B | $2.91B | $1.36B | $1.31B | $1.27B |
| Low Forecast | $2.96B | $2.91B | $1.36B | $2.80B | $1.27B | $1.15B | $1.52B | $2.90B | $2.91B | $1.36B | $1.31B | $1.27B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.86% | 1.19% |
Haleon's average Quarter SG&A projection for Jun 23 is $1.36B, based on 1 Wall Street analysts, with a range of $1.36B to $1.36B. The forecast indicates a 19.45% rise compared to HLN last annual SG&A of $1.14B (Mar 23).
Haleon EPS Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $0.08 | $0.04 |
| Avg Forecast | $0.18 | $0.17 | $0.10 | $0.18 | $0.17 | $0.07 | $0.09 | $0.18 | $0.18 | $0.10 | $0.08 | $1.55 |
| High Forecast | $0.18 | $0.17 | $0.10 | $0.18 | $0.17 | $0.07 | $0.09 | $0.18 | $0.18 | $0.10 | $0.08 | $1.55 |
| Low Forecast | $0.18 | $0.17 | $0.10 | $0.18 | $0.17 | $0.07 | $0.09 | $0.18 | $0.18 | $0.10 | $0.08 | $1.55 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.03% |
According to 1 Wall Street analysts, Haleon's projected average Quarter EPS for Jun 23 is $0.10, with a low estimate of $0.10 and a high estimate of $0.10. This represents a 14.49% increase compared to HLN previous annual EPS of $0.08 (Mar 23).
Haleon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $2.00 | $16.00 | 700.00% | Buy |
| EBS | Emergent BioSolutions | $8.77 | $51.50 | 487.23% | Buy |
| ELAN | Elanco Animal Health | $12.56 | $26.50 | 110.99% | Buy |
| CTLT | Catalent | $58.69 | $76.40 | 30.18% | Hold |
| ZTS | Zoetis | $175.18 | $227.71 | 29.99% | Buy |
| LNTH | Lantheus | $115.45 | $146.25 | 26.68% | Buy |
| NBIX | Neurocrine Biosciences | $120.53 | $147.70 | 22.54% | Buy |
| VTRS | Viatris | $11.45 | $13.75 | 20.09% | Hold |
| BHC | Bausch Health Companies | $9.26 | $10.00 | 7.99% | Hold |
| TEVA | Teva Pharmaceutical Industries | $18.64 | $20.00 | 7.30% | Buy |
| PETQ | PetIQ | $30.98 | $31.00 | 0.06% | Buy |
| HCM | HUTCHMED (China) | $18.38 | $17.50 | -4.79% | Buy |
| HLN | Haleon | $9.76 | $9.15 | -6.25% | Buy |
HLN Forecast FAQ
Is Haleon a good buy?
Yes, according to 7 Wall Street analysts, Haleon (HLN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of HLN's total ratings.
What is HLN's price target?
Haleon (HLN) average price target is $9.15 with a range of $9.15 to $9.15, implying a -6.25% from its last price of $9.76. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Haleon stock go up soon?
According to Wall Street analysts' prediction for HLN stock, the company can go down by -6.25% (from the last price of $9.76 to the average price target of $9.15), down by -6.25% based on the highest stock price target, and down by -6.25% based on the lowest stock price target.
Can Haleon stock reach $15?
HLN's average twelve months analyst stock price target of $9.15 does not support the claim that Haleon can reach $15 in the near future.
What are Haleon's analysts' financial forecasts?
Haleon's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $20.58B (high $20.58B, low $20.58B), average EBITDA is $4.05B (high $4.05B, low $4.05B), average net income is $4.98B (high $4.98B, low $4.98B), average SG&A $8.48B (high $8.48B, low $8.48B), and average EPS is $0.54 (high $0.54, low $0.54). HLN's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $16.36B (high $16.36B, low $16.36B), average EBITDA is $3.22B (high $3.22B, low $3.22B), average net income is $4.72B (high $4.73B, low $4.72B), average SG&A $6.74B (high $6.74B, low $6.74B), and average EPS is $0.513 (high $0.513, low $0.512).
Did the HLN's actual financial results beat the analysts' financial forecasts?
Based on Haleon's last annual report (Dec 2022), the company's revenue was $10.86B, beating the average analysts forecast of $3.08B by 252.40%. Apple's EBITDA was $2.16B, beating the average prediction of $606.28M by 256.77%. The company's net income was $1.06B, missing the average estimation of $14.24B by -92.56%. Apple's SG&A was $4.48B, beating the average forecast of $1.27B by 253.20%. Lastly, the company's EPS was $0.23, missing the average prediction of $1.55 by -85.13%. In terms of the last quarterly report (Mar 2023), Haleon's revenue was $2.99B, missing the average analysts' forecast of $3.19B by -6.44%. The company's EBITDA was $637M, beating the average prediction of $628.01M by 1.43%. Haleon's net income was $389M, missing the average estimation of $742.01M by -47.57%. The company's SG&A was $1.14B, missing the average forecast of $1.31B by -13.67%. Lastly, the company's EPS was $0.084, beating the average prediction of $0.0805 by 4.29%